Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Seeks To Enhance Reporting Of Pediatric Adverse Events

Executive Summary

FDA plans to change the way it collects pediatric adverse event information under the Best Pharmaceuticals for Children Act

You may also be interested in...



FDA Adding More Pediatric Data To Labeling, Ponders Surveillance Options

Drug labeling will include more information on pediatric trials following a recommendation from Office of New Drugs Director John Jenkins

FDA Adding More Pediatric Data To Labeling, Ponders Surveillance Options

Drug labeling will include more information on pediatric trials following a recommendation from Office of New Drugs Director John Jenkins

Antidepressant Suicidality Should Be Regarded As Class Risk – Cmte.

Warnings on the risk of pediatric suicidality should be applied to all antidepressants, a joint FDA advisory committee concluded

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel